SCHEMBL269984

SCHEMBL269984

CCCC(C)[CH]O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28309636 1.00
SCHEMBL6082623 0.82
SCHEMBL6901425 0.80
SCHEMBL6897138 0.78 SPHK1 (0.46)
SCHEMBL467706 0.77
SCHEMBL16290113 0.77
SCHEMBL17772412 0.77
SCHEMBL2345796 0.75
SCHEMBL16167303 0.73 TSHR (0.38)
SCHEMBL269986 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111039774-A Process for producing aliphatic carboxylic acid compound and pyridine compound adduct of aliphatic ketone compound 捷恩智株式会社 2020-04-21 CN disclosed
EP-2111385-B1 Substituted alkine derivatives as anti-cancer agents UNIV LOUISVILLE RES FOUND (US) 2014-11-12 EP disclosed
US-8703829-B2 Therapeutic compounds UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2014-04-22 US disclosed
EP-1888509-B1 BENZOYL-SUBSTITUTED SERINE AMIDES BASF SE (DE) 2013-05-15 EP disclosed
EP-2567950-A1 Substituted alkine derivatives as anti-cancer agents University Of Louisville Research Foundation, Inc. (US) 2013-03-13 EP disclosed
US-20120329866-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2012-12-27 US disclosed
US-8207381-B2 1-Bromo-1,1-difluoro-non-2-yn-4-ol; 6-Bromo-6,6-difluoro-2,2-dimethyl-hex-4-yn-3-ol; anticarcinogenic, -tumor, -metastasic agents; enzyme inhibitors of modification methylases; myelodysplastic syndrome, leukemia, a solid tumor, schizophrenia, sickle cell disease, or lupus; breast, colon, brain cancers UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION (US) 2012-06-26 US disclosed
US-8133851-B2 Heteroaroyl-substituted serine amides BASF SE (DE) 2012-03-13 US disclosed
US-20110318470-A1 Method For Improving Plant Health BASF SE (DE) 2011-12-29 US disclosed
US-20110209253-A1 Method for Improving Plant Health BASF SE (DE) 2011-08-25 US disclosed
US-6833481-B2 Catalytic dehydrative isomerization TAKASAGO INTERNATIONAL CORPORATION (JP) 2004-12-21 US disclosed
EP-1295878-B1 PYRAZINONE DERIVATIVES BANYU PHARMA CO LTD (JP) 2004-09-15 EP disclosed
US-20030203907-A1 An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis MSD K.K. (JP) 2003-10-30 US disclosed
US-20030109755-A1 Process for producing 2-alkyl-2cyclopentenones TAKASAGO INTERNATIONAL CORPORATION 2003-06-12 US disclosed
EP-1316541-A1 Process for producing 2-alkyl-2-cyclopentenones Takasago International Corporation (JP) 2003-06-04 EP disclosed
EP-1295878-A1 NOVEL PYRAZINONE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-03-26 EP disclosed
EP-1199306-A1 BIARYLUREA DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-04-24 EP disclosed
EP-0539677-B1 Method of preparing a phosphine compound CYTEC TECH CORP (US) 1997-10-08 EP disclosed
US-5250736-A Reacting a phosphine with allylhalide or vinylhalide to form allyl or vinyl phosphonium salt, treating with base to desalt; bidentate ligands CYANAMID CANADA INC. (CA) 1993-10-05 US disclosed
EP-0539677-A1 Method of preparing a phosphine compound CYTEC TECHNOLOGY CORP. (US) 1993-05-05 EP disclosed